Is Plavix affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: CYP2C19

Used for: Preventing blood clots after stent placement, heart attack, or stroke

Plavix (clopidogrel) is a pharmacogenetic textbook case: the drug itself is inactive, and CYP2C19 in your liver is responsible for converting it to its active metabolite. If your CYP2C19 genotype makes you a poor metabolizer, Plavix doesn't activate effectively, and your blood stays more clot-prone than your cardiologist expects. The clinical stakes are real. Poor metabolizers on Plavix after stent placement have significantly higher rates of stent thrombosis (a clot forming in the newly placed stent), heart attack, and cardiovascular death compared to normal metabolizers on the same drug. This is one of the few pharmacogenetic scenarios where the FDA has added a boxed warning specifically advising prescribers to consider alternative therapy.

What's in Plavix

clopidogrel affected by CYP2C19

Affected by CYP2C19 · CPIC, FDA · Strong evidence

Clopidogrel is a prodrug that requires two CYP2C19-mediated oxidation steps to form its active metabolite. Roughly 2 to 5 percent of people of European descent and 15 to 20 percent of people of East Asian descent are CYP2C19 poor metabolizers. An additional 30 percent are intermediate metabolizers with partially reduced function. The active metabolite irreversibly blocks the P2Y12 platelet receptor, preventing platelet aggregation. If not enough active metabolite forms, platelets aggregate normally and the drug fails to do its job.

Read the full clopidogrel genetics guide →

Clopidogrel phenotype recommendations

Published guidance from CPIC and FDA on how clopidogrel should be dosed or substituted based on your CYP2C19 phenotype.

Phenotype	What it means	Recommendation	Evidence
Ultrarapid Metabolizer CYP2C19	Your body processes the drug faster, but the usual dose works fine.	CPIC If considering clopidogrel, use at standard dose (75 mg/day) FDA Clopidogrel - label recommended dosage and administration	Strong
Rapid Metabolizer CYP2C19	Your body processes the drug normally or slightly faster; the usual dose works fine.	CPIC If considering clopidogrel, use at standard dose (75 mg/day) FDA Clopidogrel - label recommended dosage and administration	Strong
Normal Metabolizer CYP2C19	Your body processes the drug normally; the usual dose works fine.	CPIC If considering clopidogrel, use at standard dose (75 mg/day) FDA Clopidogrel - label recommended dosage and administration	Strong
Likely Intermediate Metabolizer CYP2C19	Your body processes the drug slower, reducing its effect. Switching to a different medication is usually better.	CPIC Avoid standard dose clopidogrel (75 mg) if possible. Use prasugrel or ticagrelor at standard dose if no contraindication FDA Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.	Moderate
Intermediate Metabolizer CYP2C19	Your body processes the drug slower, reducing its effect. Switching to a different medication is usually better.	CPIC Avoid standard dose (75 mg) clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication FDA Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.	Strong
Likely Poor Metabolizer CYP2C19	Your body barely processes the drug, so it’s safer to use a different medication.	CPIC Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication FDA Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.	Strong
Poor Metabolizer CYP2C19	Your body barely processes the drug, so it’s safer to use a different medication.	CPIC Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication FDA Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.	Strong
Indeterminate CYP2C19	The impact of your genotype on response to this drug is unknown.	CPIC Initiate therapy with recommended starting dose. FDA Clopidogrel - label recommended dosage and administration	—
Not available CYP2C19	The impact of your genotype on response to this drug is unknown.	CPIC Initiate therapy with recommended starting dose. FDA Clopidogrel - label recommended dosage and administration	—

Sources: CPIC, FDA

The gene behind the guidance

CYP2C19 Cytochrome P450 2C19

CYP2C19 handles several SSRIs (citalopram, escitalopram, sertraline), proton pump inhibitors (omeprazole, esomeprazole), and the blood thinner clopidogrel. About 2 to 5 percent of people of European descent and 15 to 20 percent of people of East Asian descent are poor metabolizers. Another 30 percent carry a rapid-metabolizer variant.

Rapid metabolizers clear affected drugs before they reach therapeutic levels. Poor metabolizers accumulate the drug and feel stronger effects.

See all drugs affected by CYP2C19 →

What this means for you

If you or a family member has had a stent placed, had a heart attack, or had a stroke and is on Plavix, knowing your CYP2C19 genotype is one of the highest-value pharmacogenetic tests that exists. Poor and intermediate metabolizers should talk to their cardiologist about whether ticagrelor or prasugrel (both of which don't depend on CYP2C19 for activation) would be a safer choice. This is not an academic question. The alternative drugs exist, they work, and they cost more, but the trade-off is straightforward when the stakes are recurrent cardiac events.

FAQ

Should I ask my cardiologist to test my CYP2C19 before starting Plavix?

Yes, especially if you've had a recent stent placement or are at high cardiovascular risk. Many academic medical centers and a growing number of community cardiologists now routinely genotype CYP2C19 before starting Plavix, and some hospitals have point-of-care tests that return results in an hour. If your prescriber hasn't mentioned it, it's a reasonable thing to ask about.

What if I'm already on Plavix and it seems to be working?

Most people on Plavix are normal metabolizers and the drug works fine for them. If you've been stable on Plavix for years without recurrent cardiac events, that's a practical data point in your favor. But if you have a cardiac event while on Plavix, CYP2C19 testing is one of the first things a good cardiologist will consider as part of the workup for why the drug may have failed.

Are Brilinta (ticagrelor) and Effient (prasugrel) affected by pharmacogenetics?

Ticagrelor (Brilinta) is active as given and doesn't depend on CYP2C19 or CYP2D6 for activation. Prasugrel (Effient) is a prodrug but uses different enzymes and isn't meaningfully affected by CYP2C19 variation. Both are alternatives for patients whose CYP2C19 genotype makes Plavix unreliable.

Related medications

Find out how your genetics affect Plavix

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.